Administration Expression after Secondary Vector Expression in the Lung and Facilitates Adenovirus-Mediated Transgene Ligand Interactions Prolongs Transient Inhibition of CD 28 and CD 40
暂无分享,去创建一个
P. Linsley | M. Kay | A. Aruffo | Christopher B Wilson | D. Hollenbaugh | L. Embree | D. Schowalter | R. Albert
[1] M. Kay,et al. Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo , 1997, Nature Biotechnology.
[2] J. Zabner,et al. Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. , 1997, The Journal of clinical investigation.
[3] P. Linsley,et al. Do effector and memory T helper cells also need B7 ligand costimulatory signals? , 1997, Journal of immunology.
[4] L. Meuse,et al. Constitutive expression of murine CTLA4Ig from a recombinant adenovirus vector results in prolonged transgene expression , 1997, Gene Therapy.
[5] J. Mcghee,et al. Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene. , 1997, Journal of immunology.
[6] A. Beaudet,et al. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. , 1997, Human gene therapy.
[7] H. Zhou,et al. Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo , 1997, Journal of virology.
[8] W. Song,et al. Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors. , 1997, Human gene therapy.
[9] R. Gregory,et al. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway , 1997, Gene Therapy.
[10] M. Mehtali,et al. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression , 1997, Gene Therapy.
[11] A. Gown,et al. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[12] G. Droguett,et al. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[13] E. Butcher,et al. Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. , 1997, The Journal of clinical investigation.
[14] B. Davidson,et al. Complexes of Adenovirus with Polycationic Polymers and Cationic Lipids Increase the Efficiency of Gene Transfer in Vitro and in Vivo* , 1997, The Journal of Biological Chemistry.
[15] S. Kochanek,et al. Persistence in muscle of an adenoviral vector that lacks all viral genes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[16] R. Flavell,et al. The Cd40 ligand , 1997, Immunologic research.
[17] J. Wilson,et al. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy , 1996, Journal of virology.
[18] J. Wilson,et al. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. , 1996, Human molecular genetics.
[19] James M. Wilson,et al. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs , 1996, Journal of virology.
[20] R. Flavell,et al. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues , 1996, Journal of virology.
[21] P. Linsley,et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways , 1996, Nature.
[22] J. Bluestone,et al. CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.
[23] J. Wilson,et al. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. , 1996, Gene therapy.
[24] J. Leiden,et al. Immune responses to transgene–encoded proteins limit the stability of gene expression after injection of replication–defective adenovirus vectors , 1996, Nature Medicine.
[25] Peter S. Linsley,et al. The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells , 1996, The Journal of experimental medicine.
[26] H. Ertl,et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. , 1996, Gene therapy.
[27] M. Schuyler,et al. The Regulation of Pulmonary Immunity , 1995, Advances in Immunology.
[28] A. Pavirani,et al. Long‐term humoral and cellular immunity induced by a single immunization with replication‐defective adenovirus recombinant vector , 1995, European journal of immunology.
[29] C. Gravel,et al. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. , 1995, Human gene therapy.
[30] A. Gown,et al. Long–term hepatic adenovirus–mediated gene expression in mice following CTLA4Ig administration , 1995, Nature Genetics.
[31] M. Kay,et al. Immunomodulation to enhance gene therapy , 1995, Nature Medicine.
[32] H. Ertl,et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses , 1995, Journal of virology.
[33] J. Whitsett,et al. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. , 1995, Human gene therapy.
[34] M. Kay,et al. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. , 1995, Gene therapy.
[35] M. Kay,et al. Therapeutic serum concentrations of human alpha‐1‐antitrypsin after adenoviral‐mediated gene transfer into mouse hepatocytes , 1995, Hepatology.
[36] N. Sarvetnick,et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[37] James M. Wilson,et al. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans , 1994, Nature.
[38] H. Ertl,et al. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. , 1994, Immunity.
[39] James M. Wilson,et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis , 1994, Nature Genetics.
[40] J. Wilson,et al. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[41] M. Perricaudet,et al. Widespread long-term gene transfer to mouse skeletal muscles and heart. , 1992, The Journal of clinical investigation.
[42] R. Chanock,et al. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[43] D. Farson,et al. Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector. , 1997, Gene therapy.
[44] J Bajorath,et al. Immune regulation by CD40 and its ligand GP39. , 1996, Annual review of immunology.
[45] R. Noelle,et al. Functions of CD40 and its ligand, gp39 (CD40L). , 1996, Critical reviews in immunology.
[46] F. Graham,et al. Adenovirus-based expression vectors and recombinant vaccines. , 1992, Biotechnology.